UBS Global Healthcare Conference - CLOVER HEALTH INVESTMENTS CORP

Financial Performance:

• Year-to-date (YTD) adjusted EBITDA reached $97 million, driven by strong momentum continuing from the first two quarters.
• YTD net income totaled $62 million while growing membership at approximately 50%.
• Generated over $200 million in operating cash flow during 2026.
• Balance sheet is robust with >$500 million in cash and securities and zero debt.
• Margins are expanding due to cohort maturation, particularly with two large cohorts progressing through the early part of the maturation curve in 2027.

Guidance and Future Outlook:

• Management targets strong growth for 2027, with a specific focus on cohort maturation and earnings expansion.
• No long-term margin target set yet; the company intends to set such targets only after growth rates stabilize.
• 2027 Star rating is projected at 4.5, ensuring continued favorable payment economics into 2028.
• Anticipates significant membership growth in 2027 driven by a competitor plan exit in New Jersey (~40,000 MA members) and a broader retreat from $0 PPOs by national MCOs.
• Five-star rating allows for year-round enrollment (April–December special election period), which is expected to drive incremental growth, particularly in direct channels.

Business Segments and Product Lines:

• Medicare Advantage (MA): Core business; new member cohorts (switchers from other MA plans) show significantly better Medical Loss Ratios (MLRs) than FFS or aging members. ~85% of new members in 2026 were switchers from other MA plans, expected to rise in 2027.
• Clover Assistant: Deployed via in-network physicians and employed clinicians (CloverCare Services); serving as the primary lever for clinical impact, cost management, and cohort maturation.
• Counterpart Health: Focus is on scaling third-party lives under management to match internal Clover Assistant coverage; economics optimization is a secondary near-term goal.
• Part D: Transitioned from Caremark to OptumRx to improve cost and Star performance management; trends have been lighter than expected, particularly in non-low-income populations.
• D-SNPs/C-SNPs: No immediate plans for D-SNPs in fully integrated states (e.g., NJ) due to Medicaid MCO requirements; C-SNPs are under evaluation for 2028+ due to synergy with chronic disease management tools.

Market and Competitive Landscape:

• New Jersey: Core market benefiting from a large competitor exit (~40k members) creating acquisition opportunities.
• Competitive Dynamics: National competitors are retreating from $0 PPO products, strengthening Clover's competitive positioning in the PPO book.
• Expansion Strategy: Expansion outside NJ relies on replicating success factors (Clover Assistant coverage) and uses Counterpart Health to gain "boots on the ground" insights into market viability; avoiding heavily capitated markets like South Florida.
• Market Share: Gaining share from both market exits and superior product positioning; PPO advantage has grown as competitors shift to HMO models.

Risks and Challenges:

• Medical Trend: While inpatient utilization is favorable, there is a noted shift toward higher utilization in outpatient settings (surgery, observation, ER stays).
• Operational Scaling: Need to scale clinical operations and provider engagement density quickly in new geographies to maintain high Clover Assistant coverage rates.
• Risk Adjustment: Potential industry changes to risk adjustment models (similar to V28) remain a factor, though Clover's technology nimbleness is viewed as a mitigation strategy.
• Market Concentration: Heavy reliance on New Jersey, though management does not currently see a need to diversify contracts within existing markets.
• Star Rating Dependency: While the company claims resilience, the 4.5-star rating is critical for maintaining competitive plan designs and retention, which drives the cohort maturation strategy.

Management Commentary and Tone:

• Tone: Highly confident and optimistic; management describes 2027 as "exciting" and emphasizes a "strong engine" for growth.
• Confidence: Strong belief in the "Cohort Maturation" thesis powered by Clover Assistant as the primary driver for margin expansion and earnings growth.
• Strategic Clarity: Clear articulation of the separation between fixed cost scaling and variable growth investments, with a commitment to funding growth from existing cash flow.
• Differentiation: Emphasizes that unlike peers, Clover has verifiable, real-world data proving technology efficacy, making it a resilient growth story even without Star rating bonuses.

Analyst Questions and Answers:

• Medical Trend: Confirmed favorable trends in inpatient utilization but warned of offsetting costs in outpatient care.
• Growth Source: 2027 growth is attributed to both competitive positioning and a unique market dynamic (NJ plan exit).
• Pricing Trends: Aggregated trend assumptions appear lighter than peers due to high weighting of lower-cost new member cohorts, though individual factor assumptions are in line.
• New Member Economics: Switchers from other MA plans perform significantly better than FFS or aging members; ~85% of new members are switchers.
• Cost Management: Focus areas include increasing Clover Assistant coverage and improving provider payment integrity amidst rising billing intensity.
• D-SNP/C-SNP Strategy: D-SNPs avoided in fully integrated states; C-SNPs are a potential future product for chronic disease management.
• Star Rating Diversification: No plans to diversify contracts in existing markets; diversification may occur only if entering new territories or product types.
• Technology Sales: AI is not a barrier to selling; competitors lack the public, verifiable data results that Clover possesses.
• AI Efficiency: AI offers significant opportunities in SG&A, claims adjudication, and provider payment integrity, alongside spreading fixed costs over a larger member base.

Other Key Points:

• Clover Assistant Deployment: Two prongs: employed clinicians (scalable to any market) and network physicians (requires density to change workflow).
• Cohort Maturation: By 2028, the company could have three large cohorts maturing simultaneously, potentially creating a significant earnings tailwind.
• Capital Needs: Management asserts the balance sheet is well-positioned to fund regulatory capital needs without needing external sizing or specific debt issuance.
• Investment Priorities: Future investments will be dictated by AEP results, focusing on either continued growth or further investment in AI-driven capabilities and Clover Assistant.
• V28 Case Study: The company cites its ability to improve benefits and grow margins during the V28 implementation as proof of its operational nimbleness compared to competitors.